Juxtapid (lomitapide) Coverage Criteria
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs UnitedHealthcare prior authorization and medical-necessity coverage for Juxtapid in members with homozygous familial hypercholesterolemia. It establishes initial authorization, reauthorization, step-therapy, documentation, prescriber, combination-therapy, and authorization-duration requirements.
Step-therapy criteria were updated based on the updated FDA labeling for Repatha.
Current Juxtapid therapy may bypass the step-therapy criteria when claims history or medical records document ongoing therapy.
The requirement prohibiting combination use with PCSK9 inhibitors was removed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.